phalloidine and Hepatitis-C

phalloidine has been researched along with Hepatitis-C* in 2 studies

Reviews

1 review(s) available for phalloidine and Hepatitis-C

ArticleYear
[Acute liver failure--medical viewpoints].
    Praxis, 2006, Nov-29, Volume: 95, Issue:48

    Acute liver failure is a rare disease that can cause death in the majority of untreated cases. Sudden loss of liver function in the absence of a preexisting liver disease is considered the true form and has to be distinguished from impaired function following exacerbation of an underlying liver disease (acute or chronic failure). Common causes include acute viral hepatitis, drug induced liver injury (DILI) and toxins. The loss of the excretory and synthetic function of the liver marks the clinical presentation and results in icterus, coagulopathy and encephalopathy. Additionally impairment of renal function and sepsis occur and contribute to the high mortality of this disease. The activation of cell death mechanisms (apoptosis) leading to a reductio of viable, functional liver tissue is considered to be an important pathophysiologic mechanism. Curative therapy of this disease includes liver transplantation that has been performed in Germany for the first time in 1969. In the year 2004 a total of 91 liver transplantation were performed for acute liver failure (10.3% of all transplants) in German transplant centers.

    Topics: Acute Disease; Adolescent; Adult; Amanita; Anti-Bacterial Agents; Antidotes; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Germany; Hepatic Encephalopathy; Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Hepatitis E; Hepatocytes; Humans; Liver Failure, Acute; Liver Transplantation; Mushroom Poisoning; Phalloidine; Plasmapheresis; Prognosis; Renal Dialysis; Renal Insufficiency; Substance-Related Disorders

2006

Other Studies

1 other study(ies) available for phalloidine and Hepatitis-C

ArticleYear
Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile.
    Hepatology (Baltimore, Md.), 1997, Volume: 26, Issue:3

    Antibodies to nuclei (ANA), smooth muscle (SMA), and liver/kidney microsomes type 1 (anti-LKM1) may occur in chronic hepatitis C. Distinct subspecificities, including ANA with the homogeneous pattern (ANA-H) and SMA with antiactin specificity (SMA-AA), are found in autoimmune hepatitis (AIH). This study was performed to characterize the hepatitis C virus (HCV)-associated autoantibodies and to evaluate their influence on the profile of the disease. Two hundred ninety consecutive patients with chronic hepatitis C and 35 control cases with AIH were screened for autoantibodies by indirect immunofluorescence (IFL) at 1:40 serum dilution. The ANA pattern was defined by IFL on HEp-2 cells and the SMA-AA identified by the presence of at least two of the following elements: 1) SMA(T) or SMA(G) pattern by IFL on kidney sections; 2) XR1 precipitating system by counterimmunoelectrophoresis; or 3) typical pattern by IFL on liver sections from phalloidin-intoxicated rats. ANA, SMA, and anti-LKM1 occurred in 9%, 20%, and 6% of chronic hepatitis C cases, respectively. The overall prevalence of autoantibodies was 30% (87 of 290). Compared with AIH, HCV-associated ANA and SMA exhibited ANA-H and SMA-AA at a lower prevalence (38% vs. 71%, P = .04 and 8% vs. 87%, P < .000001, respectively) and had a lower median titer (1:80 vs. 1:320, P < .001 and 1:40 vs. 1:320, P < .000001, respectively). The concomitant positivity for ANA-H and SMA-AA was detected in none of the HCV cases, but in 46% of AIH sera (P < .000001). Two parameters were independently associated with the autoantibodies in chronic hepatitis C: high alanine transaminase (ALT) serum levels (F = 14.04) and female gender (F = 5.03). At the univariate analysis, patients with autoantibodies had a more severe portal-periportal necroinflammation (median Scheuer's score: 2.05 vs. 1.64, P = .003). The presence of autoantibodies did not influence the response to interferon (IFN). In chronic hepatitis C, serum autoantibodies are common, but their subspecificities are distinct from those occurring in AIH. Whereas the absence of ANA-H and/or SMA-AA does not exclude AIH, the characterization of ANA and SMA may help to discriminate between the two conditions. As compared with the seronegative counterpart, autoantibody-positive chronic hepatitis C is more common in females and exhibits a more severe biochemical and histological activity. The response to IFN therapy, however, is similar.

    Topics: Analysis of Variance; Animals; Antibodies, Antinuclear; Autoantibodies; Autoimmune Diseases; Female; Fluorescent Antibody Technique, Indirect; Hepacivirus; Hepatitis; Hepatitis C; Humans; Liver; Liver Function Tests; Mice; Microsomes; Middle Aged; Muscle, Smooth; Phalloidine; Rats

1997